Single Dose of PF-06835919 Escalation Study in Healthy Adult Subjects

Completed · Phase 1 · Has a placebo group

Conditions studied: Non-alcoholic Fatty Liver Disease

In brief

The purpose of this study is to assess the safety, tolerability, and pharmacokinetics of a single dose of PF-06835919 in healthy adult subjects.

Key facts

Study ID

NCT02974374

Run by

Pfizer

People needed

16

Starts

2016-10-01

Expected to finish

2017-01-01

Last updated by the study team

2017-12-15

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Healthy males and female of non-childbearing potential;
• Body Mass Index 21.5 to 30.5 kg/m2 (inclusive);
• Total body weight >50 kg (110 lbs).

You may not qualify if…

• Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing).

Where it is running

• Pfizer New Haven Clinical Research Unit — New Haven, Connecticut, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.